[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1515752T1 - Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije - Google Patents

Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije

Info

Publication number
SI1515752T1
SI1515752T1 SI200331524T SI200331524T SI1515752T1 SI 1515752 T1 SI1515752 T1 SI 1515752T1 SI 200331524 T SI200331524 T SI 200331524T SI 200331524 T SI200331524 T SI 200331524T SI 1515752 T1 SI1515752 T1 SI 1515752T1
Authority
SI
Slovenia
Prior art keywords
hypertension
lung
heart
treatment
kidney disease
Prior art date
Application number
SI200331524T
Other languages
English (en)
Inventor
Joseph M Penninger
Michael A Crackower
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SI1515752T1 publication Critical patent/SI1515752T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
SI200331524T 2002-06-19 2003-06-19 Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije SI1515752T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38970902P 2002-06-19 2002-06-19
EP03729747A EP1515752B1 (en) 2002-06-19 2003-06-19 Ace2 activation for treatment of heart, lung and kidney disease and hypertension
PCT/CA2003/000882 WO2004000367A1 (en) 2002-06-19 2003-06-19 Ace2 activation for treatment of heart, lung and kidney disease and hypertension

Publications (1)

Publication Number Publication Date
SI1515752T1 true SI1515752T1 (sl) 2009-06-30

Family

ID=30000461

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200331524T SI1515752T1 (sl) 2002-06-19 2003-06-19 Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
SI200332334T SI2332582T1 (sl) 2002-06-19 2003-06-19 Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200332334T SI2332582T1 (sl) 2002-06-19 2003-06-19 Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije

Country Status (14)

Country Link
US (3) US7794707B2 (sl)
EP (3) EP2332582B1 (sl)
JP (1) JP4598518B2 (sl)
CN (2) CN101961493A (sl)
AT (1) ATE415175T1 (sl)
AU (1) AU2003240331B2 (sl)
CA (1) CA2489873C (sl)
CY (1) CY1108829T1 (sl)
DE (1) DE60324925D1 (sl)
DK (2) DK1515752T3 (sl)
ES (3) ES2443305T3 (sl)
PT (2) PT2332582E (sl)
SI (2) SI1515752T1 (sl)
WO (1) WO2004000367A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2332582E (pt) * 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
GB0511279D0 (en) * 2005-06-02 2005-07-13 Univ Warwick Assay
WO2008066770A2 (en) * 2006-11-22 2008-06-05 University Of Florida Research Foundation, Inc. Ace2 activator compounds and methods of use thereof
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
AT506258A1 (de) 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
EP2077119A1 (de) 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
EP3058074B1 (en) 2013-10-18 2019-02-20 Trustees Of The University Of Pennsylvania Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells
CA3082610A1 (en) 2017-11-29 2019-06-06 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2019136318A2 (en) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
CN108660205A (zh) * 2018-07-04 2018-10-16 刘城 一种糖尿病遗传风险评估试剂盒及其运用
CN110577588B (zh) * 2019-09-29 2020-12-29 苏州大学 一种凹耳蛙免疫调节肽及其应用
CN111087445B (zh) * 2019-10-14 2021-08-24 浙江大学 一种用于ace2活性检测的质谱探针及其制备方法和应用
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021197501A1 (zh) * 2020-04-02 2021-10-07 创观（苏州）生物科技有限公司 病毒不易感动物
EP4132653A4 (en) * 2020-04-11 2024-05-22 Geneticure Inc. GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE- AND POST-CORONAVIRUS INFECTIONS
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
JP7563940B2 (ja) * 2020-10-22 2024-10-08 シスメックス株式会社 呼吸器感染症に関する情報の取得方法、バイオマーカーの測定値のモニタリング方法、試薬キット、呼吸器感染症に関する情報の取得装置及びコンピュータプログラム
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
US20240358008A1 (en) * 2021-08-31 2024-10-31 New York University COMPOSITIONS AND METHODS FOR SWITCHING ANTIBIOTIC RESISTANCE MARKERS PROGRESSIVELY FOR INTEGRATION (mSwAP-In)
EP4147702A1 (en) 2021-09-13 2023-03-15 Medizinische Universität Graz Novel combination of heparin and ace2 decoys for the treatment of covid-19
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same
WO2023144625A2 (en) * 2022-01-27 2023-08-03 The Chinese University Of Hong Kong Enhanced hace2-based neutralizing agents against sars-cov-2 infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5753226A (en) 1995-04-11 1998-05-19 The Trustees Of The University Of Pennsylvania Methods of enhancing epithelial cell proliferation
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US6224584B1 (en) 1997-01-14 2001-05-01 Eclipse Surgical Technologies, Inc. Therapeutic and diagnostic agent delivery
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5792851A (en) 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
US5851788A (en) 1997-01-31 1998-12-22 The Burnham Institute Nucleic acid encoding a family of acetyl-coenzyme-A transporter proteins, and products related thereto
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US5997509A (en) 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
TR200103094T2 (tr) 1999-04-30 2002-03-21 Millennium Pharmaceuticals, Inc. ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
MXPA02003924A (es) 1999-10-21 2002-10-23 Ciba Sc Holding Ag Proceso para la preparacion de derivados de pirimidos(5, 4-g)pteridina.
JP4520569B2 (ja) 2000-02-18 2010-08-04 照彦 豊岡 拡張型心筋症の遺伝子治療剤
US6303830B1 (en) * 2000-03-15 2001-10-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
AU2001284794A1 (en) * 2000-08-09 2002-02-18 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and uses therefor
PT2332582E (pt) * 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão

Also Published As

Publication number Publication date
US20050251873A1 (en) 2005-11-10
CN101961493A (zh) 2011-02-02
EP1515752A1 (en) 2005-03-23
CA2489873C (en) 2016-08-09
EP2332582B1 (en) 2013-10-30
DE60324925D1 (de) 2009-01-08
DK1515752T3 (da) 2009-03-23
SI2332582T1 (sl) 2014-03-31
PT1515752E (pt) 2009-03-05
US20120251520A1 (en) 2012-10-04
AU2003240331A1 (en) 2004-01-06
US20100311822A1 (en) 2010-12-09
CN1671425A (zh) 2005-09-21
EP1515752B1 (en) 2008-11-26
DK2332582T3 (da) 2014-01-20
WO2004000367A1 (en) 2003-12-31
EP2047867B1 (en) 2013-05-22
AU2003240331B2 (en) 2008-08-21
ES2443305T3 (es) 2014-02-18
CN1671425B (zh) 2013-07-10
CA2489873A1 (en) 2003-12-31
ES2424971T3 (es) 2013-10-10
JP2006504637A (ja) 2006-02-09
ES2318137T3 (es) 2009-05-01
EP2332582A1 (en) 2011-06-15
EP2047867A1 (en) 2009-04-15
ATE415175T1 (de) 2008-12-15
JP4598518B2 (ja) 2010-12-15
US8211426B2 (en) 2012-07-03
PT2332582E (pt) 2014-01-28
CY1108829T1 (el) 2014-04-09
US8802084B2 (en) 2014-08-12
US7794707B2 (en) 2010-09-14

Similar Documents

Publication Publication Date Title
PT2332582E (pt) Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
EP1578354A4 (en) TARGETS, METHODS AND REAGENTS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ATE330038T1 (de) Nukleinsäure-biosensor
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
EP1439393A3 (en) Detection methods using TIMP 1 for colon cancer diagnosis
AU2003286597A8 (en) Biosensor having hematocrit and oxygen biases
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
CA2531451A1 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
EP1637603A4 (en) FOR A PROTEIN WITH D-MILKYLIC ACID DEHYDROGENASE ACTIVITY, DNA AND USE THEREOF
WO2005089310A3 (en) Breath test for oral malodor
WO2006034879A3 (en) Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2007060647A3 (en) A method for detecting or monitoring sepsis by analysing cytokine mrna expression levels
WO2003031942A8 (en) Reagents and methods useful for detecting diseases of the breast
NO20043438L (no) Etterproving av fiskeopprinnelse basert pa nukleinsyremonstergjenkjennelse
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
CY1114765T1 (el) Ενεργοποιηση ace2 για θεραπεια ασθενειας της καρδιας, του πνευμονα και του νεφρου και υπερτασης
EP1766391A4 (en) NEW DIAGNOSTIC METHODS FOR THE TREATMENT OF P. AERUGINOSA INFECTIONS AND REAGENTS FOR THESE METHODS
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2006019984A3 (en) Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome